Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Outstanding (Weighted Average) (2022 - 2025)

BioXcel Therapeutics has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $12.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $12.2 million for Q4 2025, up 381.58% from a year ago — trailing twelve months through Dec 2025 was $12.2 million (up 381.58% YoY), and the annual figure for FY2025 was $12.2 million, up 381.58%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $12.2 million at BioXcel Therapeutics, up from $9.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for BTAI hit a ceiling of $29.3 million in Q3 2023 and a floor of $1.8 million in Q4 2023.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $10.6 million (2025), compared with a mean of $15.2 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 93.5% in 2023 and later skyrocketed 381.58% in 2025.
  • BioXcel Therapeutics' Shares Outstanding (Weighted Average) stood at $28.0 million in 2022, then tumbled by 93.5% to $1.8 million in 2023, then skyrocketed by 39.21% to $2.5 million in 2024, then skyrocketed by 381.58% to $12.2 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $12.2 million (Q4 2025), $9.0 million (Q3 2025), and $6.3 million (Q2 2025) per Business Quant data.